Celera and Medco Enter Research Collaboration to Evaluate Effect of KIF6 Testing on Compliance with Statin Therapy in Patients with Cardiovascular Disease


External link:* http://medco.mediaroom.com/index.php?s=43&item=397

Celera Corporation and Medco Health Solutions, Inc. announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases patient adherence with statin therapy.

Author: Medco and Celera

Related numbers to fix: $475 Billion

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

If approved, your first name and first initial of your last name will be published to the site with your comment.


Submit
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
3 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

* = required field

divider
* By selecting an external link, you will be leaving the Making Medicine Smarter website and linking to another website which may be governed by a separate and different Terms of Use and Privacy Policy.

Medco is a registered trademark and Medco Making Medicine Smarter is a trademark of Medco Health Solutions, Inc.
Copyright 2009 Medco Health Solutions, Inc. All Rights Reserved.